Characteristics of patients diagnosed with NET and surviving at least 12 months who reported at least one ESAS score, stratified by primary tumor site
| Variable . | . | All NETs (n = 2,721) . | Gastroenteric (n = 1,269) . | Pancreatic (n = 522) . | Bronchopulmonary (n = 585) . | Others (n = 345) . | p valuea . |
|---|---|---|---|---|---|---|---|
| Age, years | 18–29 | 90 (3.3) | 56 (4.4) | 10 (1.9) | 16 (2.7) | 8 (2.3) | <.001 |
| 30–39 | 183 (6.7) | 80 (6.3) | 44 (8.4) | 28 (4.8) | 31 (9.0) | ||
| 40–49 | 378 (13.9) | 198 (15.6) | 87 (16.7) | 46 (7.9) | 47 (13.6) | ||
| 50–59 | 668 (24.5) | 332 (26.2) | 150 (28.7) | 126 (21.5) | 60 (17.4) | ||
| 60–69 | 761 (28.0) | 335 (26.4) | 149 (28.5) | 185 (31.6) | 92 (26.7) | ||
| 70–79 | 462 (17.0) | 194 (15.3) | 66 (12.6) | 137 (23.4) | 65 (18.8) | ||
| 80–99 | 179 (6.6) | 74 (5.8) | 16 (3.1) | 47 (8.0) | 41 (12.1) | ||
| Female sex | 1,417 (52.1) | 635 (50.0) | 240 (46.0) | 351 (60.0) | 191 (55.4) | <.001 | |
| Diagnosis time period | Before 2010 | 718 (26.4) | 319 (25.1) | 130 (24.9) | 157 (26.8) | 112 (32.5) | .041 |
| After 2010 | 2,003 (73.6) | 950 (74.9) | 392 (75.1) | 428 (73.2) | 233 (67.5) | ||
| Urban residence | 2,457 (90.3) | 1,141 (89.9) | 488 (93.5) | 519 (88.7) | 309 (89.6) | .12 | |
| Socioeconomic status, quintile | 1st (lowest) | 498 (18.3) | 220 (17.4) | 82 (15.9) | 114 (19.6) | 79 (22.9) | .026 |
| 2nd | 489 (18.0) | 220 (17.3) | 96 (18.4) | 108 (18.5) | 65 (18.8) | ||
| 3rd | 527 (19.4) | 244 (19.2) | 95 (18.2) | 108 (18.5) | 80 (23.2) | ||
| 4th | 608 (22.3) | 311 (24.5) | 112 (21.5) | 127 (21.7) | 58 (16.8) | ||
| 5th (highest) | 599 (22.0) | 273 (21.5) | 136 (26.1) | 127 (21.7) | 63 (18.3) | ||
| High comorbidity burden (ACG ≥10) | 665 (24.4) | 288 (22.7) | 132 (25.3) | 165 (28.2) | 80 (23.2) | .048 | |
| Metastatic status | None | 1,244 (45.7) | 568 (44.8) | 261 (50.0) | 292 (49.9) | 123 (35.7) | <.001 |
| Synchronous | 1,089 (40.0) | 553 (43.6) | 165 (31.6) | 213 (36.4) | 158 (45.8) | ||
| Metachronous | 388 (14.3) | 148 (11.7) | 96 (18.4) | 80 (13.7) | 64 (18.6) | ||
| Therapy | Surgery | 1,574 (57.8) | 946 (74.5) | 300 (57.5) | 274 (46.8) | 54 (15.7) | <.001 |
| Liver embolization | 276 (10.1) | 149 (11.7) | 58 (11.1) | 29 (5.0) | 40 (11.6) | <.001 | |
| Chemotherapy | 967 (35.5) | 340 (26.8) | 194 (37.2) | 255 (43.6) | 178 (51.6) | <.001 | |
| Radiation therapy | 501 (18.4) | 82 (6.5) | 59 (11.3) | 229 (39.1) | 131 (38.0) | <.001 | |
| Variable . | . | All NETs (n = 2,721) . | Gastroenteric (n = 1,269) . | Pancreatic (n = 522) . | Bronchopulmonary (n = 585) . | Others (n = 345) . | p valuea . |
|---|---|---|---|---|---|---|---|
| Age, years | 18–29 | 90 (3.3) | 56 (4.4) | 10 (1.9) | 16 (2.7) | 8 (2.3) | <.001 |
| 30–39 | 183 (6.7) | 80 (6.3) | 44 (8.4) | 28 (4.8) | 31 (9.0) | ||
| 40–49 | 378 (13.9) | 198 (15.6) | 87 (16.7) | 46 (7.9) | 47 (13.6) | ||
| 50–59 | 668 (24.5) | 332 (26.2) | 150 (28.7) | 126 (21.5) | 60 (17.4) | ||
| 60–69 | 761 (28.0) | 335 (26.4) | 149 (28.5) | 185 (31.6) | 92 (26.7) | ||
| 70–79 | 462 (17.0) | 194 (15.3) | 66 (12.6) | 137 (23.4) | 65 (18.8) | ||
| 80–99 | 179 (6.6) | 74 (5.8) | 16 (3.1) | 47 (8.0) | 41 (12.1) | ||
| Female sex | 1,417 (52.1) | 635 (50.0) | 240 (46.0) | 351 (60.0) | 191 (55.4) | <.001 | |
| Diagnosis time period | Before 2010 | 718 (26.4) | 319 (25.1) | 130 (24.9) | 157 (26.8) | 112 (32.5) | .041 |
| After 2010 | 2,003 (73.6) | 950 (74.9) | 392 (75.1) | 428 (73.2) | 233 (67.5) | ||
| Urban residence | 2,457 (90.3) | 1,141 (89.9) | 488 (93.5) | 519 (88.7) | 309 (89.6) | .12 | |
| Socioeconomic status, quintile | 1st (lowest) | 498 (18.3) | 220 (17.4) | 82 (15.9) | 114 (19.6) | 79 (22.9) | .026 |
| 2nd | 489 (18.0) | 220 (17.3) | 96 (18.4) | 108 (18.5) | 65 (18.8) | ||
| 3rd | 527 (19.4) | 244 (19.2) | 95 (18.2) | 108 (18.5) | 80 (23.2) | ||
| 4th | 608 (22.3) | 311 (24.5) | 112 (21.5) | 127 (21.7) | 58 (16.8) | ||
| 5th (highest) | 599 (22.0) | 273 (21.5) | 136 (26.1) | 127 (21.7) | 63 (18.3) | ||
| High comorbidity burden (ACG ≥10) | 665 (24.4) | 288 (22.7) | 132 (25.3) | 165 (28.2) | 80 (23.2) | .048 | |
| Metastatic status | None | 1,244 (45.7) | 568 (44.8) | 261 (50.0) | 292 (49.9) | 123 (35.7) | <.001 |
| Synchronous | 1,089 (40.0) | 553 (43.6) | 165 (31.6) | 213 (36.4) | 158 (45.8) | ||
| Metachronous | 388 (14.3) | 148 (11.7) | 96 (18.4) | 80 (13.7) | 64 (18.6) | ||
| Therapy | Surgery | 1,574 (57.8) | 946 (74.5) | 300 (57.5) | 274 (46.8) | 54 (15.7) | <.001 |
| Liver embolization | 276 (10.1) | 149 (11.7) | 58 (11.1) | 29 (5.0) | 40 (11.6) | <.001 | |
| Chemotherapy | 967 (35.5) | 340 (26.8) | 194 (37.2) | 255 (43.6) | 178 (51.6) | <.001 | |
| Radiation therapy | 501 (18.4) | 82 (6.5) | 59 (11.3) | 229 (39.1) | 131 (38.0) | <.001 | |
Values are n (%) reporting column percentages, or median (interquartile range).
aComparison between primary tumor site groups, using chi‐square test.
Abbreviations: ACG, aggregated clinical groups; ESAS, Edmonton Symptom Assessment System; NET, neuroendocrine tumor.
Characteristics of patients diagnosed with NET and surviving at least 12 months who reported at least one ESAS score, stratified by primary tumor site
| Variable . | . | All NETs (n = 2,721) . | Gastroenteric (n = 1,269) . | Pancreatic (n = 522) . | Bronchopulmonary (n = 585) . | Others (n = 345) . | p valuea . |
|---|---|---|---|---|---|---|---|
| Age, years | 18–29 | 90 (3.3) | 56 (4.4) | 10 (1.9) | 16 (2.7) | 8 (2.3) | <.001 |
| 30–39 | 183 (6.7) | 80 (6.3) | 44 (8.4) | 28 (4.8) | 31 (9.0) | ||
| 40–49 | 378 (13.9) | 198 (15.6) | 87 (16.7) | 46 (7.9) | 47 (13.6) | ||
| 50–59 | 668 (24.5) | 332 (26.2) | 150 (28.7) | 126 (21.5) | 60 (17.4) | ||
| 60–69 | 761 (28.0) | 335 (26.4) | 149 (28.5) | 185 (31.6) | 92 (26.7) | ||
| 70–79 | 462 (17.0) | 194 (15.3) | 66 (12.6) | 137 (23.4) | 65 (18.8) | ||
| 80–99 | 179 (6.6) | 74 (5.8) | 16 (3.1) | 47 (8.0) | 41 (12.1) | ||
| Female sex | 1,417 (52.1) | 635 (50.0) | 240 (46.0) | 351 (60.0) | 191 (55.4) | <.001 | |
| Diagnosis time period | Before 2010 | 718 (26.4) | 319 (25.1) | 130 (24.9) | 157 (26.8) | 112 (32.5) | .041 |
| After 2010 | 2,003 (73.6) | 950 (74.9) | 392 (75.1) | 428 (73.2) | 233 (67.5) | ||
| Urban residence | 2,457 (90.3) | 1,141 (89.9) | 488 (93.5) | 519 (88.7) | 309 (89.6) | .12 | |
| Socioeconomic status, quintile | 1st (lowest) | 498 (18.3) | 220 (17.4) | 82 (15.9) | 114 (19.6) | 79 (22.9) | .026 |
| 2nd | 489 (18.0) | 220 (17.3) | 96 (18.4) | 108 (18.5) | 65 (18.8) | ||
| 3rd | 527 (19.4) | 244 (19.2) | 95 (18.2) | 108 (18.5) | 80 (23.2) | ||
| 4th | 608 (22.3) | 311 (24.5) | 112 (21.5) | 127 (21.7) | 58 (16.8) | ||
| 5th (highest) | 599 (22.0) | 273 (21.5) | 136 (26.1) | 127 (21.7) | 63 (18.3) | ||
| High comorbidity burden (ACG ≥10) | 665 (24.4) | 288 (22.7) | 132 (25.3) | 165 (28.2) | 80 (23.2) | .048 | |
| Metastatic status | None | 1,244 (45.7) | 568 (44.8) | 261 (50.0) | 292 (49.9) | 123 (35.7) | <.001 |
| Synchronous | 1,089 (40.0) | 553 (43.6) | 165 (31.6) | 213 (36.4) | 158 (45.8) | ||
| Metachronous | 388 (14.3) | 148 (11.7) | 96 (18.4) | 80 (13.7) | 64 (18.6) | ||
| Therapy | Surgery | 1,574 (57.8) | 946 (74.5) | 300 (57.5) | 274 (46.8) | 54 (15.7) | <.001 |
| Liver embolization | 276 (10.1) | 149 (11.7) | 58 (11.1) | 29 (5.0) | 40 (11.6) | <.001 | |
| Chemotherapy | 967 (35.5) | 340 (26.8) | 194 (37.2) | 255 (43.6) | 178 (51.6) | <.001 | |
| Radiation therapy | 501 (18.4) | 82 (6.5) | 59 (11.3) | 229 (39.1) | 131 (38.0) | <.001 | |
| Variable . | . | All NETs (n = 2,721) . | Gastroenteric (n = 1,269) . | Pancreatic (n = 522) . | Bronchopulmonary (n = 585) . | Others (n = 345) . | p valuea . |
|---|---|---|---|---|---|---|---|
| Age, years | 18–29 | 90 (3.3) | 56 (4.4) | 10 (1.9) | 16 (2.7) | 8 (2.3) | <.001 |
| 30–39 | 183 (6.7) | 80 (6.3) | 44 (8.4) | 28 (4.8) | 31 (9.0) | ||
| 40–49 | 378 (13.9) | 198 (15.6) | 87 (16.7) | 46 (7.9) | 47 (13.6) | ||
| 50–59 | 668 (24.5) | 332 (26.2) | 150 (28.7) | 126 (21.5) | 60 (17.4) | ||
| 60–69 | 761 (28.0) | 335 (26.4) | 149 (28.5) | 185 (31.6) | 92 (26.7) | ||
| 70–79 | 462 (17.0) | 194 (15.3) | 66 (12.6) | 137 (23.4) | 65 (18.8) | ||
| 80–99 | 179 (6.6) | 74 (5.8) | 16 (3.1) | 47 (8.0) | 41 (12.1) | ||
| Female sex | 1,417 (52.1) | 635 (50.0) | 240 (46.0) | 351 (60.0) | 191 (55.4) | <.001 | |
| Diagnosis time period | Before 2010 | 718 (26.4) | 319 (25.1) | 130 (24.9) | 157 (26.8) | 112 (32.5) | .041 |
| After 2010 | 2,003 (73.6) | 950 (74.9) | 392 (75.1) | 428 (73.2) | 233 (67.5) | ||
| Urban residence | 2,457 (90.3) | 1,141 (89.9) | 488 (93.5) | 519 (88.7) | 309 (89.6) | .12 | |
| Socioeconomic status, quintile | 1st (lowest) | 498 (18.3) | 220 (17.4) | 82 (15.9) | 114 (19.6) | 79 (22.9) | .026 |
| 2nd | 489 (18.0) | 220 (17.3) | 96 (18.4) | 108 (18.5) | 65 (18.8) | ||
| 3rd | 527 (19.4) | 244 (19.2) | 95 (18.2) | 108 (18.5) | 80 (23.2) | ||
| 4th | 608 (22.3) | 311 (24.5) | 112 (21.5) | 127 (21.7) | 58 (16.8) | ||
| 5th (highest) | 599 (22.0) | 273 (21.5) | 136 (26.1) | 127 (21.7) | 63 (18.3) | ||
| High comorbidity burden (ACG ≥10) | 665 (24.4) | 288 (22.7) | 132 (25.3) | 165 (28.2) | 80 (23.2) | .048 | |
| Metastatic status | None | 1,244 (45.7) | 568 (44.8) | 261 (50.0) | 292 (49.9) | 123 (35.7) | <.001 |
| Synchronous | 1,089 (40.0) | 553 (43.6) | 165 (31.6) | 213 (36.4) | 158 (45.8) | ||
| Metachronous | 388 (14.3) | 148 (11.7) | 96 (18.4) | 80 (13.7) | 64 (18.6) | ||
| Therapy | Surgery | 1,574 (57.8) | 946 (74.5) | 300 (57.5) | 274 (46.8) | 54 (15.7) | <.001 |
| Liver embolization | 276 (10.1) | 149 (11.7) | 58 (11.1) | 29 (5.0) | 40 (11.6) | <.001 | |
| Chemotherapy | 967 (35.5) | 340 (26.8) | 194 (37.2) | 255 (43.6) | 178 (51.6) | <.001 | |
| Radiation therapy | 501 (18.4) | 82 (6.5) | 59 (11.3) | 229 (39.1) | 131 (38.0) | <.001 | |
Values are n (%) reporting column percentages, or median (interquartile range).
aComparison between primary tumor site groups, using chi‐square test.
Abbreviations: ACG, aggregated clinical groups; ESAS, Edmonton Symptom Assessment System; NET, neuroendocrine tumor.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
